Philip is a Principal Scientist within the Advanced Technology Team at the Wyss Institute focusing on translational therapeutics and genetic medicines. Philip is a pharmacologist and systems biologist with extensive experience in lipid nanoparticle delivery and tolerability as well as viral vector-based genetic medicines. Prior to joining the Wyss, Philip worked as a Senior Scientist within the Delivery Biology team at Tessera Therapeutics. He and his team screened 100+ novel ionizable lipids and formulations in vivo for liver indications including PKU and AATD, as well as contributing to extrahepatic targets including in vivo CAR-T and HSCs for cancer and Sickle Cell Disease, respectively. This work resulted in IND approved compositions entering clinical trials this year. Earlier, Philip led a non-viral DNA delivery project for long-term correction of hemophilia A at Bioverativ, a Sanofi Company. Philip earned his PhD in Molecular and Systems Pharmacology at Emory University and completed his postdoctoral training at Queen’s University focusing on genetic medicines for rare bleeding disorders, hemophilia A and von Willebrand’s Disease.